You prove my point by typing. Same dollar amount just different # of shares.
Answer the question WHY?
And again let me know when he sells a big chunk thats when I'm out.
You sir are a dumb #$%$.
.104 or 2.60 is the same just different # of shares same amount in dollars.
But the question you should ask is why they want that pay in stock if it is going to zero?
They are long and know something you do not.
Let me know when they sell a substantial amount, they will have to report.
The United States Food and Drug Administration (FDA) reviews and must ultimately approve any new drug as "safe and effective" before it can be marketed for sale in the United States. The question of whether the agency is too cautious in its reviews (delaying access to critically needed treatments), or too fast in issuing approvals (potentially exposing patients to undetected risks from new products), has long been a subject of public debate.
This study attempts to provide a more objective examination of the FDA's performance by examining disparities in review and approval times across 12 review divisions within the FDA's Center for Drug Evaluation and Research (CDER). After reviewing nearly 200 products accounting for 80 percent of new drug and biologic launches from 2004 to 2012, the authors find wide variation in division performance. In fact, the most productive divisions (Oncology and Antivirals) approve new drugs roughly twice as fast as the CDER average and three times faster than the least efficient divisions—without the benefit of greater resources, reduced complexity of task, or reduction in safety. The authors estimate that a modest narrowing of the CDER divisional productivity gap would reduce drug costs by nearly $900 million annually. The worth to patients, however, would be far greater if the agency could accelerate access to an additional generation of (about 25) drugs. Greater agency efficiency in approving a single generation of drugs would be worth about $4 trillion in value to patients, from enhanced U.S. life expectancy. To reap such gains, this study encourages Congress and the FDA to more closely evaluate the agency's most efficient drug review divisions, and apply the lessons learned across CDER. We also propose a number of reforms that the FDA and Congress should consider to improve efficiency, transparency, and consistency at the divisional level.
Project FDA is a Manhattan Institute initiative that aims to reform the FDA to meet 21st century challenges. Under the leadership of former FDA commissioner Dr. Andrew von Eschenbach, Project FDA promotes reforms that can enable the FDA to offer a more predictable, transparent, and efficient pathway for bringing safe and effective new products to patients.
Medicine is on the cusp of a radical transformation. New sciences and technologies are poised to allow physicians to personalize treatment for every cancer patient; arrest or prevent the development of Alzheimer's disease; and radically lower health care costs by reducing the prevalence of expensive chronic diseases. Unfortunately, today's FDA has struggled to adapt its regulations to new scientific advances.
TheCure in the CodeProject FDA believes the FDA can become a bridge for innovation, rather than a barrier to it, and that this can be achieved without sacrificing patient safety. For instance, advances in molecular medicine that allow companies to target specific sub-groups of patients, combined with electronic health records, should allow the FDA to streamline and improve time consuming and expensive pre-market product testing that can take a decade or more, and implement vigorous post-market surveillance of "real world" patients after drugs or devices demonstrate safety and efficacy in early testing. This approach will not only accelerate access to innovative products; it should enhance efforts to safeguard public health.
Project FDA will educate the public on the FDA's vital role in advancing medical innovation; highlight the potential for new sciences to improve health while also lowering costs; and collaborate with patients' groups, industry stakeholders, and policymakers to modernize the FDA's policies and procedure
the knuckleheads will chime in with it ain't wurth nuthin! So let their childish rants continue.
All discussions will now be post split. Shorts will talk pre split its their play book.
I sold 12000 shares post split that i have accumulated on the dips into the 2.25 range at 3.25. I believe the stock will sink after the initial surge in short covering and will buy those shares back at a discount when future financing takes place. Still holding 9000 share post split position.
A secondary benefit of a reverse split is that by reducing the shares outstanding and share float, the stock becomes harder to borrow, making it difficult for short sellers to short the stock. The limited liquidity may also widen the bid-ask spread, which in turn deters trading and short selling.
No wonder the trolls have been so busy.
The seemingly insatiable appetite for dealmaking in the pharmaceuticals sector helped push US stocks higher.
A raft of deals lifted the S&P 500 healthcare sector 1.1 per cent higher to 853.70, taking the index’s gains since the year began to 7.8 per cent and making it the best performing sector this year.
Catamaran was among the day’s big winners, jumping nearly 25 per cent to $60.15 after the fourth-biggest pharmacy benefit manager in the US struck a deal to be acquired by rival UnitedHealth for $12.8bn in cash.
UnitedHealth, which is offering $61.50 a share, is planning to merge Catamaran with its Optum Rx unit, the sector’s number three.
UnitedHealth expected the combined companies to increase annual revenues from $100bn a year to $400bn a year by 2020. Shares in UnitedHealth were up 3.4 per cent at $122.06.
Elsewhere, Horizon Pharma agreed to buy Hyperion Therapeutics for nearly $1bn in cash. The deal, which will boost Horizon’s drug portfolio, helped shares in the Dublin-based company gain more than 14 per cent to $24.89. Hyperion rose 7.4 per cent to $45.90.
Auspex Pharmaceutical surged more than 41 per cent to $100.32 after Israel’s Teva Pharmaceutical Industries agreed to buy the central nervous system drug specialist for $3.2bn, including debt.
MLV & Co’s professionals offer a unique approach to supporting a company’s growth and profitability. We provide a variety of advisory services to our clients including mergers and acquisitions, divestitures, strategic guidance, fairness opinions/valuation, royalty monetization, project finance and restructuring.
They did not invest 16.5 million in December to throw it away in April.
But knuckleheads know better. Let the noise begin.
A sockpuppet is an online identity used for purposes of deception. The term, a reference to the manipulation of a simple hand puppet made from a sock, originally referred to a false identity assumed by a member of an Internet community who spoke to, or about, themselves while pretending to be another person. The term now includes other misleading uses of online identities, such as those created to praise, defend or support a person or organization, or to circumvent a suspension or ban from a website. A significant difference between the use of a pseudonym and the creation of a sockpuppet is that the sockpuppet poses as an independent third-party unaffiliated with the puppeteer. Many online communities attempt to block sockpuppets. Not yahoo.
Welcome aboard TS that has been the scenario I have been predicting for over a year now.
Why else would Dr M take no salary and continue to drive RCPI forward? Knuckleheads will come back with their blather, but there is no other answer. Phase 3 of Nilvadipine is scheduled for primary completion 5/16 with study completion 12/17.
Also it is fully funded, how did he, Dr Mullan, do it and why do they think he went to Europe with AC?
Their idiotic answers to follow.
McKeon has 20-25 million shares.
He has invested a lot into this company and believes in the new management.
He and other large investors, Tradewinds 15-20 million, will not let it fail before science is proven or not.
They also, I beleive, forced JW, who still owns 10 million shares, out after the gov debacle.
That is around 50 million shares that will not go down easy and will control the outcome of RCPI.
But not on this board by dr quackenbush in fantasy tokyo.
It will be decided by Dr Mullan and a team from Quotient Clinical and the MHRA in Europe then the FDA will feel the pressure.
Dr Mullan thinks so much of this he and his management team are working for zip, nada, nothing until the science is on the table.
He will deserve a large raise when that happens, most likely through stock options .
Good luck and as they say in Vegas "only gamble what you can afford to lose".